InvestorsHub Logo
icon url

RobinF

12/19/15 8:57 AM

#67218 RE: Greymatter1 #67217

Let's get back to reality! Doctors are still prescribing Gen Lovaza and Lovaza at around 80k prescriptions per week. If Vascepa is "fish oil", Lovaza/Gen Lovaza certainly is! And Vascepa is a superior product without the side effects and raised LDL. Once the information is out there with continued results with patients, V will not be ignored. We are seeing excellent script growth rate with refill prescriptions which says the product is working.
icon url

bidmark

12/19/15 9:26 AM

#67222 RE: Greymatter1 #67217

How did you decide that "Greymatter1" was an appropriate username?
icon url

jessellivermore

12/19/15 9:32 AM

#67223 RE: Greymatter1 #67217

Greymatter...

With due respect for the fact you have been following this issue for several years, I am going to have to disagree with most of your statements. No doubt you are as frustrated as the rest of us, but things are hardly as bleak as you imagine.

It is clear that being pessimistic in the in thing lately..We have posters lined up extolling the great risk involved here, and I ask you if you believe this is the case, why are you still here?

I know why I am here. I am not in the least bit worried about the R-I results and consider the risk-reward ratio as favorable as any situation I have encountered in my lifetime. We have population studies, previous outcomes trial (JELIS) and over a thousand scientific papers that all support the notion this drug is going super nova..For those of you that worry about Nemesis, the sun's evil twin, astroids, magetars, mantle plume explosions and other extinction events, they are out there..but don't hold your breath.

True Amarin has faced some hurtles and traps, but nothing compared to many of the world's great advances. Think Amarin has had to overcome difficulties, check out Philo T. Farnsworth's battle against RCA for the rights to television, or Marconi's struggle with radio.

R-I is tracking as expected and without safety issues. We do not know at present if the risk reduction will be high enough to halt the trial at interim, but that has not been ruled out, and IMO the chances are excellent this will be the case.

Faint heart n'er won the fair lady...

":>) JL

icon url

rafunrafun

12/19/15 10:29 AM

#67226 RE: Greymatter1 #67217

Where do you come up with 2025????
icon url

Biobillionair

12/20/15 7:12 AM

#67233 RE: Greymatter1 #67217

At current script growth rate, Amain will be in the black for the end of 2016...this is my worse case scenario.

At some point the FDA will be forced to implement Generic Labeling rules. Generic Lovaza is going to have to admit there's an unknown Cardiovascular risk with the significant bump in LDL compared to V. Generics have been protected from the lawyers for far too long.

BB